reports
BB Biotech AG : Q2 18 preview: Mixed portfolio performance; FX tailwin...
>Flat performance in Q2 despite FX tailwind - In Q2 2018, BB Biotech’s share price in EUR increased just slightly – by 2% – and thus underperform its sector benchmark, the Nasdaq Biotech (up 7% in EUR). Despite a currency tailwind from the stronger USD, BB Biotech’s Q2 2018 overall portfolio performance was unimpressive due to mixed performances among individual portfolio positions (see below). In Q2 2018 BB Biotech’s portfolio NAV decreased 1% yoy. The NAV premium st...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.